Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-3

Firing on all cylinders. Even ignoring everything apart from IHL-42x, 675, and 216A, we have a solid company with immense potential.

IHL-42x: Proven to work in humans. Results simply need to be replicated in a larger trial and then we can unlock a big market. Also considering the company can implement any learnings from the POC trial, I fail to see how the pivotal trial won't be a success.

IHL-216A: FDA support, and good level of de-risking due to what is known about the constituent drugs.

IHL-675A: Good level of de-risking due to what is known about the constituent drugs. Phase I passed with flying colours.

A lot of biotechs have a lot more unknowns within their pipelines. A biotech with a de-risked pipeline with a lot of cash on hand is exactly where you want to be in this sector, imo. Not only that, but we are really positioning ourselves as a leader in the specific sub-sector focusing on cannabinoid-based therapeutics. Any big pharma looking to establish themselves in that space, IHL will be the first place to look I'd imagine. What, you think they're going to stand up a comparable pipeline and patent portfolio in-house?